Riskpilot← Back to searchSign inGet full accessCereus Pharma AB
ABActiveOrg 5590661897Jakobsdalsgatan 46Research and experimental development on natural sciences and engineering · NACE 7210Est. 20160 employees
Revenue 2025
SEK 95,1M
EBITDA margin
99.6%
+27386% vs 2024
Equity ratio
79.2%
Financial strength
Net profit 2025
SEK 75,7M
+13498519% vs 2024
| Revenue | SEK 95,1M | — |
| EBITDA | SEK 94,7M | +27386% |
| Net profit | SEK 75,7M | +13498519% |
| Total assets | SEK 95,9M | +19188% |
| Equity | SEK 75,9M | +41422% |
| Employees | 0 | — |
Legal name
Cereus Pharma AB
Org number
5590661897
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
13 juni 2016
Share capital
SEK 60 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-10-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska bedriva utveckling och försäljning av konsulttjänster och produkter såsom läkemedel, medicinska hjälpmedel och tester, patent- och patenträttigheter med anknytning till medicinska behandlingar för sömnrelaterade andningsstörningar såsom obstruktiv sömnapne samt därmed förenlig verksamhet.
Address
Jakobsdalsgatan 46
Email
ludger.grote@lungall.gu.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 3 120 | 3 179 | 13 555 | 0 | 0 | 0 | — | 95 100 |
| Staff expenses | — | — | — | — | — | — | — | — | — | −15 |
| EBITDA | 34 | 1 960 | 3 081 | 3 129 | 12 903 | −625 | −619 | −631 | −347 | 94 723 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | — | — | — | — |
| EBIT | 34 | 1 960 | 3 081 | 3 129 | 12 903 | −625 | −619 | −631 | −347 | 94 723 |
| Net financials | — | — | — | −6 | −2 | — | −1 | 0 | 0 | 784 |
| Profit before tax | 34 | 1 960 | 3 081 | 3 122 | 10 500 | −25 | 10 | 14 | 8 | 95 377 |
| Tax | −8 | −432 | −679 | −670 | −2 248 | −0 | −9 | −14 | −7 | −19 650 |
| Net profit | 26 | 1 528 | 2 402 | 2 452 | 8 252 | −25 | 1 | −0 | 1 | 75 727 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 107 | 2 089 | 3 336 | 3 452 | 10 980 | 2 094 | 1 369 | 738 | 497 | 95 892 |
| Equity | 86 | 1 614 | 2 606 | 2 665 | 8 457 | 182 | 182 | 182 | 183 | 75 910 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — |
| Short-term debt | 21 | 475 | 730 | 788 | 123 | 113 | 17 | 31 | 144 | 19 682 |
| Total debt | 21 | 475 | 730 | 788 | 123 | 113 | 17 | 31 | 144 | 19 682 |
EBITDA margin
99.6%
This company
15.8%
Market median
+530% vs market
20162025
Equity ratio
79.2%
This company
38.2%
Market median
+107% vs market
20162025
Return on equity
99.8%
This company
18.4%
Market median
+442% vs market
20162025
Net profit margin
79.6%
This company
8.1%
Market median
+883% vs market
20162025
Asset turnover
0.99×
This company
1.12×
Market median
+12% vs market
20162025
Debt / equity
0.26×
This company
0.62×
Market median
+58% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-11-01 – 2025-10-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-11-01 – 2024-10-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-11-01 – 2023-10-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-11-01 – 2022-10-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-11-01 – 2021-10-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-11-01 – 2020-10-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-10-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-07-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AC Audit | Audit | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Cereus Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Cecilia Hedin | Audit | 0 companies |
| Jan Anders Hedner | Chairman | 0 companies |
| Kaj Sven Stenlöf | Board of Directors | 0 companies |
| Ludger Benno Grote | Board of Directors | 0 companies |